Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Jonathan E RosenbergSe Hoon ParkVadim KozlovTu Van DaoDaniel CastellanoJian-Ri LiSom D MukherjeeKathryn HowellsHannah DryMark C LanasaRoss StewartDean F BajorinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Adding olaparib to durvalumab did not improve survival outcomes in an unselected mUC population. Efficacy outcomes with durvalumab were similar to those reported for other anti-programmed cell death-1/programmed cell death ligand-1 agents. However, the results of secondary analyses suggest a potential role for PARP inhibition in patients with UC harboring HRRm.